vs
INSEEGO CORP.（INSG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
INSEEGO CORP.的季度营收约是REGENXBIO Inc.的1.6倍（$48.4M vs $30.3M），INSEEGO CORP.净利率更高（1.0% vs -221.3%，领先222.3%），REGENXBIO Inc.同比增速更快（43.0% vs 0.6%），INSEEGO CORP.自由现金流更多（$11.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 13.6%）
Inseego Corp是全球领先的5G及物联网解决方案提供商，主打移动热点、边缘计算设备及云端设备管理平台产品，客户覆盖全球范围内的电信运营商、企业及公共部门。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
INSG vs RGNX — 直观对比
营收规模更大
INSG
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出42.4%
0.6%
净利率更高
INSG
高出222.3%
-221.3%
自由现金流更多
INSG
多$64.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $48.4M | $30.3M |
| 净利润 | $469.0K | $-67.1M |
| 毛利率 | 42.2% | — |
| 营业利润率 | 2.7% | -190.0% |
| 净利率 | 1.0% | -221.3% |
| 营收同比 | 0.6% | 43.0% |
| 净利润同比 | 182.9% | -31.2% |
| 每股收益（稀释后） | $-0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INSGRGNX
| Q4 25 | $48.4M | $30.3M | ||
| Q3 25 | $45.9M | $29.7M | ||
| Q2 25 | $40.2M | $21.4M | ||
| Q1 25 | $31.7M | $89.0M | ||
| Q4 24 | $48.1M | $21.2M | ||
| Q3 24 | $54.0M | $24.2M | ||
| Q2 24 | $51.6M | $22.3M | ||
| Q1 24 | $37.5M | $15.6M |
净利润INSGRGNX
| Q4 25 | $469.0K | $-67.1M | ||
| Q3 25 | $1.4M | $-61.9M | ||
| Q2 25 | $507.0K | $-70.9M | ||
| Q1 25 | $-1.6M | $6.1M | ||
| Q4 24 | $-566.0K | $-51.2M | ||
| Q3 24 | $9.0M | $-59.6M | ||
| Q2 24 | $624.0K | $-53.0M | ||
| Q1 24 | $-4.5M | $-63.3M |
毛利率INSGRGNX
| Q4 25 | 42.2% | — | ||
| Q3 25 | 41.6% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 47.3% | — | ||
| Q4 24 | 37.3% | 70.2% | ||
| Q3 24 | 34.8% | 48.8% | ||
| Q2 24 | 36.4% | 52.5% | ||
| Q1 24 | 35.3% | 72.6% |
营业利润率INSGRGNX
| Q4 25 | 2.7% | -190.0% | ||
| Q3 25 | 4.7% | -176.3% | ||
| Q2 25 | 3.2% | -296.3% | ||
| Q1 25 | -1.3% | 13.6% | ||
| Q4 24 | 3.7% | -242.1% | ||
| Q3 24 | 1.9% | -256.6% | ||
| Q2 24 | 3.6% | -251.3% | ||
| Q1 24 | -7.9% | -408.8% |
净利率INSGRGNX
| Q4 25 | 1.0% | -221.3% | ||
| Q3 25 | 3.1% | -208.3% | ||
| Q2 25 | 1.3% | -331.8% | ||
| Q1 25 | -5.0% | 6.8% | ||
| Q4 24 | -1.2% | -241.3% | ||
| Q3 24 | 16.6% | -246.3% | ||
| Q2 24 | 1.2% | -237.7% | ||
| Q1 24 | -11.9% | -405.4% |
每股收益（稀释后）INSGRGNX
| Q4 25 | $-0.02 | $-1.30 | ||
| Q3 25 | $0.03 | $-1.20 | ||
| Q2 25 | $-0.03 | $-1.38 | ||
| Q1 25 | $-0.16 | $0.12 | ||
| Q4 24 | $0.62 | $-0.99 | ||
| Q3 24 | $-0.06 | $-1.17 | ||
| Q2 24 | $-0.02 | $-1.05 | ||
| Q1 24 | $-0.44 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-4.0M | $102.7M |
| 总资产 | $93.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INSGRGNX
| Q4 25 | $24.9M | $230.1M | ||
| Q3 25 | $14.6M | $274.2M | ||
| Q2 25 | $13.2M | $323.3M | ||
| Q1 25 | $35.1M | $267.9M | ||
| Q4 24 | $39.6M | $234.7M | ||
| Q3 24 | $12.0M | $255.5M | ||
| Q2 24 | $49.0M | $290.4M | ||
| Q1 24 | $12.3M | $338.7M |
股东权益INSGRGNX
| Q4 25 | $-4.0M | $102.7M | ||
| Q3 25 | $-7.7M | $161.5M | ||
| Q2 25 | $-10.5M | $213.7M | ||
| Q1 25 | $-13.0M | $274.2M | ||
| Q4 24 | $-12.9M | $259.7M | ||
| Q3 24 | $-85.1M | $301.4M | ||
| Q2 24 | $-101.8M | $348.3M | ||
| Q1 24 | $-105.6M | $390.7M |
总资产INSGRGNX
| Q4 25 | $93.8M | $453.0M | ||
| Q3 25 | $85.8M | $525.2M | ||
| Q2 25 | $83.1M | $581.0M | ||
| Q1 25 | $93.0M | $490.9M | ||
| Q4 24 | $100.0M | $466.0M | ||
| Q3 24 | $113.4M | $519.1M | ||
| Q2 24 | $149.6M | $569.4M | ||
| Q1 24 | $122.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $11.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 24.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 25.50× | — |
| 过去12个月自由现金流最近4个季度 | $6.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流INSGRGNX
| Q4 25 | $12.0M | $-52.3M | ||
| Q3 25 | $3.2M | $-56.0M | ||
| Q2 25 | $-4.5M | $-49.3M | ||
| Q1 25 | $-3.5M | $33.6M | ||
| Q4 24 | $-14.2M | $-31.6M | ||
| Q3 24 | $14.8M | $-40.5M | ||
| Q2 24 | $27.6M | $-45.5M | ||
| Q1 24 | $5.2M | $-55.5M |
自由现金流INSGRGNX
| Q4 25 | $11.6M | $-52.8M | ||
| Q3 25 | $3.1M | $-56.5M | ||
| Q2 25 | $-4.7M | $-49.7M | ||
| Q1 25 | $-3.5M | $32.6M | ||
| Q4 24 | $-14.3M | $-32.7M | ||
| Q3 24 | $14.8M | $-40.9M | ||
| Q2 24 | $27.6M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率INSGRGNX
| Q4 25 | 24.0% | -174.0% | ||
| Q3 25 | 6.7% | -189.9% | ||
| Q2 25 | -11.6% | -232.8% | ||
| Q1 25 | -11.0% | 36.6% | ||
| Q4 24 | -29.7% | -154.2% | ||
| Q3 24 | 27.4% | -168.9% | ||
| Q2 24 | 53.5% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度INSGRGNX
| Q4 25 | 0.7% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率INSGRGNX
| Q4 25 | 25.50× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | -8.81× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 44.31× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INSG
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
